Glycated HSA Fluorecein Boronic Acid small molecule (tool compound)

Protein glycation, also known as non-enzymatic glycosylation, has been implicated in various disease states and is therefore an important biomarker for ageing and age-related chronic diseases such as diabetes, cardiovascular diseases, autoimmune diseases, cancer, and Alzheimer’s disease. However their analysis is challenging due to the complexity of the protein-carbohydrate adducts. Fluorescent boronic acids like these […]

Contributors

Inventor	Institute
Marta P. Pereira Morais	University of Bath

Cat. #:	154473
Research Fields:	Neurobiology;Biochemistry;Immunology

Alternate name:	AGEs
Product description:	Protein glycation, also known as non-enzymatic glycosylation, has been implicated in various disease states and is therefore an important biomarker for ageing and age-related chronic diseases such as diabetes, cardiovascular diseases, autoimmune diseases, cancer, and Alzheimer's disease. However their analysis is challenging due to the complexity of the protein-carbohydrate adducts. Fluorescent boronic acids like these enable the detection and identification of individual glycated proteins in…
Additional notes:	This small molecule has been used to identify glycated proteins in human serum, insect hemolymph, and mouse brain homogenates.

Primary target:	Advanced Glycation Endproducts (AGE); specifically Glycated Human Serum Albumin (HSA). Also binds ApoA-I protein

Shipping conditions:	Dry Ice

References:	Pereira Morais et al. 2013. Sci Rep. 3:1437. PMID: 23531746.

Unfortunately this tool is not available through our online checkout process. Please contact our team directly to obtain further information on accessing this tool.

Enquire about this Tool

If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Request a license

Get technical support

New to CancerTools?

We are a trusted, non-profit platform for cancer research products, part of Cancer Research UK – by sourcing your cancer research tools from us you help fund future cancer research.

Find out more

Related Tools for Small molecules

Cat. #

Tool Name

151711

MGMT inhibitor Lomeguatrib Small Molecule (Tool Compound)

Key Info

Cat. #:	151711
Sub-type:	Inhibitor
Availability:	Please enquire for quantities and pricing
Application:	Lomeguatrib (20 mg/kg/day for 5 days) combined with Temozolomide (100 mg/kg/day for 5 days) produces a substantial tumour growth delay: median tumour quintupling time is increased by 22 days without any significant increase in toxicity, while neither of the two drugs administrated along show any antitumor activity. Lomeguatrib inactivates ATase and enhances the anti-tumour effect of Temozolomide in A375M human melanoma xenografts model. Lomeguatrib, at a single dose of 20 mg/kg i.p., produces…

View Tool

151712

CDK7 inhibitor BS-181 Small Molecule (Tool Compound)

Key Info

Cat. #:	151712
Sub-type:	Inhibitor
Availability:	Please enquire for quantities and pricing
Application:	BS-181 is stable in vivo with a plasma elimination half-life in mice of 405 minutes after i.p. administration of 10 mg/kg. BS-181 inhibits the growth of MCF-7 xenografts in the nude mice model in a dose-dependent manner, with 25% and 50% reduction in tumor growth after 2 weeks of treatment at 10 mg/kg/day and 20 mg/kg/day, respectively without apparent toxicity. BS-181 is a small molecule inhibitor of CDK7 in a cell-free environment, which displays more potential activity than roscovitine with IC 50 of 510 nM. Among the CDKs and other 69 kinases from many different classes, BS-181 shows high inhibitory selectivity for CDK7, inhibits CDK2 at concentrations lower than 1 ÎźM which being inhibited 35-fold less potently (IC50 with 880 nM) than CDK7, shows slight inhibition for CDK1, CDK4, CDK5, CDK6 and CDK9 with IC50 values higher than 3.0 ÎźM, and only shows inhibition for several kinases from other classes at high concentrations (>10 ÎźM). BS-181 promotes cell cycle arrest and inhibits the cancer cell growth of a range of tumor types, including breast, lung, prostate and colorectal cancer with IC50 in the range of 11.5-37 ÎźM. In MCF-7 cells, BS-181 inhibits the phosphorylation of the CDK7 substrate RNA polymerase II COOH-terminal domain (CTD), and promotes cell cycle arrest and apoptosis to inhibit the growth of cancer cell lines.

View Tool

151889

DNA-PK inhibitor NU7441 Small Molecule (Tool Compound)

Key Info

Cat. #:	151889
Sub-type:	Inhibitor
Availability:	Please enquire for quantities and pricing
Application:	NU7441 intraperitoneally administrated at dose of 10 mg/kg maintains for at least 4 hours shows nontoxic and increases etoposide-induced tumor growth delay 2-fold in mice bearing SW620 xenografts. NU7441 increases the persistence of ÎłH2AX foci after ionizing radiationâinduced or etoposide-induced DNA damage. NU7441 (0.5 ÎźM or 1 ÎźM) appreciably increases G2-M accumulation induced by ionizing radiation, etoposide, and doxorubicin in both SW620 and LoVo cells. NU7441 causes persistence of d…

View Tool

152625

Mps1 inhibitor CCT251455 Small Molecule (Tool Compound)

Key Info

Cat. #:	152625
Sub-type:	Inhibitor
Availability:	Please enquire for quantities and pricing
Application:	CCT251455 displays a favorable oral pharmacokinetic profile, shows dose-dependent inhibition of MPS1 in an HCT116 human tumor xenograft model, and is an attractive tool compound to elucidate further the therapeutic potential of MPS1 inhibition. In Female Balb/C mice it had an oral bioavailabilty of 83%.

View Tool

152786

Nucleolar Luminophore Ag-1 Small Molecule (Tool Compound)

Key Info

Cat. #:	152786
Sub-type:	Luminophore
Availability:	Please enquire for quantities and pricing

View Tool

By Category

By Cancer Type

More

Glycated HSA Fluorecein Boronic Acid small molecule (tool compound)

Contributors

Related Tools for Small molecules

Tool enquiry